Global Artificial Pancreas Device System Market Size By Type (Control-to-Range (CTR) System, Threshold Suspended Device System), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 20...

The Global Artificial Pancreas Device System Market was valued at USD 4.2 billion in 2023 and is projected to reach USD 9.8 billion by 2031, growing at a CAGR of 11.2% during the forecast period 2023-2031. The increasing prevalence of diabetes, advancements in medical technology, and rising awareness regarding automated insulin delivery systems are the key factors driving the market growth. Artificial pancreas device systems are emerging as a revolutionary solution for managing Type 1 diabetes by continuously monitoring glucose levels and delivering insulin in real-time, reducing the risk of hypoglycemia and improving patient quality of life.

Drivers

Rising Prevalence of Diabetes

The growing global burden of diabetes, particularly Type 1 diabetes, has significantly increased the demand for artificial pancreas systems. With millions of people affected worldwide, the need for efficient glucose management systems is becoming more urgent.

Technological Advancements in Closed-Loop Systems

Continuous innovation in closed-loop insulin delivery systems, AI-powered glucose monitoring, and advanced algorithms for insulin dosing have revolutionized diabetes management, making artificial pancreas systems more accurate and effective.

Increasing Adoption of Automated Insulin Delivery Devices

As patients seek more convenient and less invasive diabetes management solutions, the adoption of automated insulin delivery devices is increasing. These devices improve treatment adherence and reduce the frequency of manual insulin injections.

Restraints

High Cost of Artificial Pancreas Systems

The high upfront cost of artificial pancreas systems and their ongoing maintenance expenses can be a barrier to widespread adoption, particularly in developing countries with limited healthcare funding.

Regulatory Challenges and Approval Complexities

Stringent regulatory requirements and lengthy clinical trials required for the approval of artificial pancreas systems can delay product launches and increase development costs for manufacturers.

Opportunity

Expansion in Emerging Markets

With increasing healthcare investments and rising awareness of diabetes management in Asia-Pacific and Latin America, the artificial pancreas device system market has significant growth potential in these regions.

Integration of AI and Machine Learning

The use of AI and machine learning algorithms in artificial pancreas systems can optimize insulin delivery, improve real-time glucose control, and further enhance treatment outcomes.

Government Initiatives for Diabetes Management

Governments worldwide are implementing programs to subsidize diabetes management technologies, including automated insulin delivery systems, which could fuel market growth.

Market by System Type Insights

Hybrid Closed-Loop Systems Hold the Largest Market Share

The Hybrid Closed-Loop (HCL) System segment accounted for the largest market share in 2023. These systems partially automate insulin delivery by adjusting basal insulin levels while requiring patients to manually input mealtime boluses. Their widespread adoption is driven by their cost-effectiveness and reliability.

Fully Closed-Loop Systems Expected to Grow Rapidly

Fully closed-loop systems are projected to witness the highest growth rate during the forecast period. These advanced systems offer complete automation, eliminating the need for patient intervention and significantly improving diabetes management outcomes.

Market by End-Use Insights

Hospitals and Clinics Dominate the Market

The Hospitals & Clinics segment accounted for over 45% of the market share in 2023, as healthcare professionals increasingly recommend artificial pancreas systems for inpatient diabetes management and post-surgical care.

Homecare Settings Gaining Traction

The Homecare Segment is expected to grow at a significant CAGR due to the rising preference for at-home diabetes management solutions and self-monitoring devices.

Market by Regional Insights

North America Leads the Market

North America dominated the Artificial Pancreas Device System Market in 2023, accounting for over 40% of the market share. The high prevalence of diabetes, advanced healthcare infrastructure, and strong presence of key players contribute to this region’s leadership.

Asia-Pacific Poised for Rapid Growth

The Asia-Pacific region is expected to witness the highest CAGR during the forecast period, driven by increasing diabetes prevalence, growing healthcare investments, and expanding access to advanced diabetes management technologies.

Competitive Scenario

Key players operating in the Global Artificial Pancreas Device System Market include:

Medtronic plc

Tandem Diabetes Care, Inc.

Insulet Corporation

Beta Bionics, Inc.

Bigfoot Biomedical, Inc.

Eli Lilly and Company

Diabeloop SA

Cellnovo Group SA

Dexcom, Inc.

Abbott Laboratories

These companies are focusing on technological advancements, strategic collaborations, and regulatory approvals to expand their market presence.

Key Market Developments

2023: Medtronic launched a next-generation hybrid closed-loop insulin delivery system with AI-powered glucose monitoring.

2024: Tandem Diabetes Care received FDA approval for its fully automated artificial pancreas system, enhancing insulin delivery efficiency.

2025: Eli Lilly partnered with a leading AI healthcare company to integrate machine learning-based insulin dosing algorithms into its artificial pancreas devices.

Scope of Work – Global Artificial Pancreas Device System Market